Market Overview - The medical services sector increased by 0.15% on November 28, with Baihua Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Stock Performance - Baihua Pharmaceutical (600721) closed at 10.11, with a rise of 10.01% and a trading volume of 394,400 shares, amounting to a transaction value of 386 million [1] - ST Zhongzhu (600568) saw a closing price of 2.71, up 5.04%, with a trading volume of 757,700 shares [1] - Chengda Pharmaceutical (301201) closed at 47.94, increasing by 4.79% with a trading volume of 86,400 shares [1] - Other notable performers include Wanbang Pharmaceutical (301520) at 41.95 (+2.07%) and Haoyuan Pharmaceutical (688131) at 76.01 (+1.89%) [1] Capital Flow - The medical services sector experienced a net outflow of 224 million from institutional investors and 116 million from retail investors, while retail investors saw a net inflow of 340 million [2] - The capital flow data indicates that Baihua Pharmaceutical had a net inflow of 89.89 million from institutional investors, while it faced a net outflow of 60.58 million from retail investors [3] - Chengda Pharmaceutical recorded a net inflow of 25.64 million from institutional investors, with a net outflow of 33.20 million from retail investors [3]

Core Insights - Chinese innovative pharmaceutical companies are transforming from participants in global biotechnology transactions to dominant players, leveraging significant R&D and cost advantages [1][2] - The role of these companies has shifted from being technology importers to important exporters, with License-out transactions becoming a key growth driver [1][3] Group 1: Market Position and Trends - Chinese pharmaceutical companies account for approximately 30% of the global total in business development (BD) transactions [2] - Domestic companies are actively positioning themselves in innovative drug R&D, characterized by a "fast, good, and cost-effective" approach [2] - The R&D pipeline of domestic companies has become a crucial source for overseas firms seeking to introduce new products [2] Group 2: Revenue Sources and Transaction Dynamics - BD revenue has become a significant income source for domestic innovative drug companies, with a notable shift from License-in to License-out transactions since 2021 [3] - The proportion of License-out transactions in the total BD transactions has increased from 45% in 2021 to 91% in 2024 [3] - Internationalization and expansion into overseas markets are now vital for revenue growth among domestic innovative drug companies [3] Group 3: Research Focus and Investment Recommendations - The small nucleic acid drug market is experiencing robust growth, with significant commercial, clinical, and BD transaction activity [4] - Multinational corporations (MNCs) continue to rely heavily on China for key supply chain components, particularly in raw materials and intermediates [4] - Investment recommendations include various innovative drug companies and raw material suppliers, highlighting a diverse range of potential opportunities in the sector [4]

Core Insights - The medical services sector experienced a slight increase of 0.45% on November 26, with Lanwei Medical leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Medical Services Sector Performance - Lanwei Medical (301060) closed at 10.79, up 7.90%, with a trading volume of 410,000 shares and a transaction value of 444 million yuan [1] - Sunshine Nuohuo (688621) closed at 68.55, up 7.63%, with a trading volume of 78,800 shares and a transaction value of 537 million yuan [1] - ST Zhongzhu (600568) closed at 2.70, up 5.06%, with a trading volume of 853,900 shares and a transaction value of 230 million yuan [1] - Chengdu Xian Dao (688222) closed at 23.40, up 2.45%, with a trading volume of 110,000 shares and a transaction value of 260 million yuan [1] - Other notable performers include Yaokang Bio (688046) and Kailai Ying (002821), with increases of 2.03% and 2.02% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 307 million yuan from institutional investors, while retail investors experienced a net outflow of 219 million yuan [2] - Major stocks like Yao Ming Kang De (603259) and Chengda Pharmaceutical (301201) had significant capital movements, with net inflows of 26.1 million yuan and 10.4 million yuan respectively [3] - Conversely, stocks like Bi De Pharmaceutical (688073) and Haochen Medical (002622) faced net outflows of 4.6% and 2.07% respectively [2][3]

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

Market Overview - The medical services sector increased by 1.65% on November 24, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Notable stock performances include: - Chengda Pharmaceutical (301201) closed at 46.40, down 3.25% with a trading volume of 129,800 shares and a turnover of 613 million yuan - Yaner Eye Hospital (300015) closed at 11.55, down 1.20% with a trading volume of 684,000 shares and a turnover of 797 million yuan - International Medical (000516) closed at 4.65, up 0.87% with a trading volume of 119,800 shares and a turnover of 55.6 million yuan [1] Capital Flow - The medical services sector experienced a net outflow of 170 million yuan from institutional investors and 158 million yuan from retail investors, while retail investors saw a net inflow of 327 million yuan [3] - Key capital flows for specific stocks include: - WuXi AppTec (603259) had a net inflow of 251 million yuan from institutional investors but a net outflow of 91.72 million yuan from retail investors - Tiger Med (300347) saw a net inflow of 62.56 million yuan from institutional investors but a net outflow of 6.44 million yuan from retail investors [3]

Core Insights - The pharmaceutical MNC supply chain has extremely high entry barriers, requiring years for supplier certification through cross-departmental audits in technology, quality, EHS, and compliance. Once included in the qualified supplier list, a strong lock-in effect is formed, making it difficult for new entrants to disrupt the existing supply structure even if they meet technical standards, thus demonstrating a strong first-mover advantage [4][7]. - MNCs demand far more than conventional quality compliance, emphasizing full-process controllability and risk management capabilities. Compliance with guidelines such as EU GMP and ICHQ is required, along with the establishment of traceability systems and safety stock. Any process changes or relocation of production sites must undergo strict and time-consuming certification [4][7]. - In procurement decisions, MNCs are relatively insensitive to price factors, prioritizing the integrity of the supply chain over cost. For MNCs, API costs represent only a small portion of their terminal formulation sales, leading them to pay a premium for stable, traceable, and zero major quality incident supply capabilities, viewing supply chain resilience as a core competitive advantage rather than a cost item. Thus, entering the MNC supply chain often means effectively avoiding "price internalization" [4][7]. - Investment recommendations include innovative drug and device companies such as Furuya Co., Aonlikang, Shutaishen, Weichuang Bio, and others. From the perspective of CXO and raw materials, companies like WuXi AppTec, Jiuzhou Pharmaceutical, Chengda Pharmaceutical, and others are suggested for attention [4][7]. Market Performance Overview - As of November 21, 2025, the TTM-PE of the pharmaceutical and biotechnology industry is 48.84 times, which is 100% higher than the historical lowest PE valuation of 24.38 times on January 3, 2019. The premium rate relative to the CSI 300 is 252%, exceeding the historical lowest valuation premium of 124% on February 6, 2018, by 128 percentage points, and is 11 percentage points higher than the average valuation premium rate of 241% over the past decade [8][12]. - From November 17 to November 21, 2025, the pharmaceutical and biotechnology sector experienced a decline of 6.88%, ranking 22nd among 27 sub-industries. The chemical raw materials sector saw the largest decline at -8.60% [12][15]. Industry Dynamics - Pfizer's Class 1 new drug, Matacizumab, was approved for marketing on November 21, 2025, for the routine prevention and treatment of bleeding in patients with severe hemophilia A or B [20]. - Boehringer Ingelheim's Class 1 new drug, BI764198, was proposed for inclusion as a breakthrough therapy on November 18, 2025, targeting primary focal segmental glomerulosclerosis [21]. - The PD-1 inhibitor H drug, Surulutumab, developed by Fuhong Hanlin, was officially included as a breakthrough therapy on November 20, 2025, for gastric cancer treatment [22]. - On November 17, 2025, FDA approved the biosimilar of Tysabri, developed by Sandoz, for multiple sclerosis and Crohn's disease [23].

Macro Strategy - The LPR remained unchanged in November, with the 1-year and 5-year rates at 3.00% and 3.50% respectively, indicating stable monetary policy despite weak macro data in October [2][3] - A-share indices experienced significant declines from November 17 to 21, with the Shanghai Composite Index down 3.90% and the ChiNext Index down 6.15%, primarily due to reduced expectations for a December rate cut by the Federal Reserve [3][4] - All primary industries in the A-share market declined, with energy metals and communication equipment showing the highest cumulative gains for 2025 at 83.18% and 78.97% respectively [5][6] Investment Recommendations - For the long term, 2026 is expected to be a year of growth driven by the "14th Five-Year Plan," with a stable A-share market anticipated [7] - Short-term strategies should focus on sectors benefiting from long-term capital inflows, traditional sectors related to "anti-involution," and consumer areas such as motorcycles and medical services [7] North Exchange Overview - As of November 21, 2025, the North Exchange had 284 listed stocks, with an average total market value of 864.16 billion yuan, a decrease of 4.16% from the previous week [10][11] - Notable new listings included Dapeng Industrial, which saw a 1211.11% increase in its stock price during its first week [10][12] Medical Services Industry - The pharmaceutical and biological sector fell by 6.88%, underperforming the Shanghai Composite Index by 3.11 percentage points [16][17] - The medical services sector's PE ratio is currently at 31.22, with a recent decline of 2.25 [18] - High-growth areas such as ADC and TIDES CDMO are recommended for investment, with companies like WuXi AppTec and WuXi Biologics highlighted [19][20][21] Automotive Industry - Yuanrong Qixing showcased 200,000 mass-produced vehicles at the Guangzhou Auto Show, aiming for a cumulative delivery of 1 million vehicles by 2026 [23][24] - The automotive sector is expected to benefit from the acceleration of intelligent technology adoption and supportive policies for vehicle consumption [25][26] - Investment opportunities are significant in the automotive and parts sectors, particularly for companies involved in smart components and electric vehicles [26][27]

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

| 301319 | 唯特偶 | 16901.65 | 21.63 | 5.79 | 电子 | | --- | --- | --- | --- | --- | --- | | 301027 | 华蓝集 团 | 13365.78 | 21.15 | -11.79 | 建筑装饰 | | 688435 | 英方软 件 | 24635.59 | 20.66 | 7.98 | 计算机 | | 920896 | 旺成科 技 | 2585.20 | 20.23 | -0.86 | 汽车 | | 301201 | 诚达药 业 | 42169.23 | 19.59 | -3.36 | 医药生物 | | 000048 | 京基智 农 | 27806.86 | 19.44 | 1.48 | 农林牧渔 | | 301097 | 天益医 疗 | 6363.03 | 19.06 | -5.35 | 医药生物 | 与杠杆资金大幅加仓股相比，有2044股融资余额出现下降，其中，融资余额降幅超过5%的有204只。国 联水产融资余额降幅最大，最新融资余额2.79亿元，与前一个交易日相比，融资余额下降了42.65%；融 资余额降幅较大的个股还有恒 ...

Core Viewpoint - Chengda Pharmaceutical Co., Ltd. plans to utilize up to 700 million yuan of idle funds for low-risk cash management to enhance capital efficiency [1][5]. Group 1: Investment Plan - The investment will be limited to low-risk, highly liquid financial products with a maturity of no more than 12 months, including agreed deposits, notice deposits, time deposits, structured deposits, and financial institution wealth management products [2]. - The total investment limit for the company and its subsidiaries is set at 700 million yuan, which can be used cyclically within the 12-month period [2]. Group 2: Risk Control - The company has established multiple risk control mechanisms, including a dynamic tracking mechanism to monitor product allocation and project progress, internal audit supervision for regular checks on investment projects, and the option for third-party audits as needed [3]. Group 3: Impact on the Company - The cash management initiative aims to ensure normal operations and fund safety while achieving value preservation and appreciation of idle funds, ultimately creating more returns for shareholders [5]. - The 700 million yuan investment amount will be assessed against the company's latest audited cash reserves to ensure alignment with the principle of "standardized operation and prudent management" [5]. Group 4: Review Process and Sponsor Opinion - The proposal has been approved by the board's audit committee and will be submitted for shareholder approval [6]. - The sponsor, Guangda Securities Co., Ltd., has confirmed that the necessary review procedures were followed and has no objections to the cash management initiative [6].